Anyang-si

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease5 trials
• COPD4 trials
• High blood pressure2 trials
• Lung cancer2 trials
• Bronchiectasis1 trial
• Childhood cancers1 trial
• Heart failure1 trial
• IgA nephropathy1 trial
• Liver and biliary tract cancer1 trial

Phase

• Phase 39 trials
• Phase 23 trials

Status

• Recruiting6 trials
• Active, not recruiting3 trials
• Completed2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca11 trials
• Alexion Pharmaceuticals, Inc.2 trials

Running trials

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

  NCT05801029· Phase 2· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD3 recruiting
• Chronic kidney disease2 recruiting
• Bronchiectasis1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Terminated

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Completed

  Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

  NCT04068168· AstraZeneca· Source